Attached files
| file | filename |
|---|---|
| 10-K - CAPRICOR THERAPEUTICS, INC. | v176034_10k.htm |
| EX-31.1 - CAPRICOR THERAPEUTICS, INC. | v176034_ex31-1.htm |
| EX-31.2 - CAPRICOR THERAPEUTICS, INC. | v176034_ex31-2.htm |
| EX-23.2 - CAPRICOR THERAPEUTICS, INC. | v176034_ex23-2.htm |
| EX-32.2 - CAPRICOR THERAPEUTICS, INC. | v176034_ex32-2.htm |
| EX-32.1 - CAPRICOR THERAPEUTICS, INC. | v176034_ex32-1.htm |
| EX-10.14 - CAPRICOR THERAPEUTICS, INC. | v176034_ex10-14.htm |
EXHIBIT
23.1
CONSENT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We
consent to the incorporation by reference in the Registration Statements of Nile
Therapeutics, Inc. on Form S-8 (File No. 333-152283) and Form S-3 (File No.
333-161339) of our report dated March 2, 2010, on the financial statements
of Nile Therapeutics, Inc. as of December 31, 2009 and for the year then
ended, and for the period from August 1, 2005 (inception) through
December 31, 2009 (which report expresses an unqualified opinion and
includes and explanatory paragraph relating to Nile Therapeutics, Inc.’s ability
to continue as a going concern) appearing in this Annual Report on Form 10-K of
Nile Therapeutics, Inc. for the year ended December 31, 2009.
/s/
Crowe Horwath LLP
New York,
New York
March 2,
2010